Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan 12;34(2):124-128.
doi: 10.1002/joa3.12031. eCollection 2018 Apr.

Impact of ranolazine on ventricular arrhythmias - A systematic review

George Bazoukis  1 , Gary Tse  2   3 , Konstantinos P Letsas  1 , Costas Thomopoulos  4 , Katerina K Naka  5 , Panagiotis Korantzopoulos  6 , Xenophon Bazoukis  7 , Paschalia Michelongona  1 , Stamatis S Papadatos  8 , Konstantinos Vlachos  1 , Tong Liu  9 , Michael Efremidis  1 , Adrian Baranchuk  10 , Stavros Stavrakis  11 , Costas Tsioufis  12
Affiliations
Review

Impact of ranolazine on ventricular arrhythmias - A systematic review

George Bazoukis et al. J Arrhythm. .

Abstract

Ranolazine is a new medication for the treatment of refractory angina. However, except its anti-anginal properties, it has been found to act as an anti-arrhythmic. The aim of our systematic review is to present the existing data about the impact of ranolazine in ventricular arrhythmias. We searched MEDLINE and Cochrane databases as well clinicaltrials.gov until September 1, 2017 to find all studies (clinical trials, observational studies, case reports/series) reported data about the impact of ranolazine in ventricular arrhythmias. Our search revealed 14 studies (3 clinical trials, 2 observational studies, 8 case reports, 1 case series). These data reported a beneficial impact of ranolazine in ventricular tachycardia/fibrillation, premature ventricular beats, and ICD interventions in different clinical settings. The existing data highlight the anti-arrhythmic properties of ranolazine in ventricular arrhythmias.

Keywords: anti‐arrhythmic drugs; ranolazine; ventricular arrhythmias; ventricular fibrillation; ventricular tachycardia.

PubMed Disclaimer

References

    1. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60:e44–164. - PubMed
    1. Rayner‐Hartley E, Sedlak T. Ranolazine: a contemporary review. J Am Heart Assoc. 2016;5:e003196. - PMC - PubMed
    1. Chaitman BR, Skettino SL, Parker JO, et al. Anti‐ischemic effects and long‐term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375–82. - PubMed
    1. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291:309–16. - PubMed
    1. Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48:566–75. - PubMed

LinkOut - more resources